CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
D. Hoffmann, B. Corleis, S. Rauch, N. Roth, J. Muehe, N. J. Halwe, L. Ulrich, C. Fricke, J. Schoen, A. Kraft, A. Breithaupt, K. Wernike, A. Michelitsch, F. Sick, C. Wylezich, , M. Beer
This study evaluates the efficacy of the CVnCoV mRNA vaccine against ancestral and emerging SARS-CoV-2 variants in a human ACE2 transgenic mouse model, showing complete protection against B.1.351.
bioRxiv · Mar 22, 2021Microbiology